Core Insights - Salesforce's earnings indicate a strong momentum in AI adoption, which may influence market sentiment positively [1] Financial Performance - The company reported significant growth in revenue, driven by increased demand for AI-related services [1] - Earnings results may challenge the prevailing bearish sentiment in the market, suggesting a potential shift in investor confidence [1] Market Sentiment - The current results could be pivotal in altering the negative outlook that has been prevalent among investors [1] - There is speculation on whether the positive earnings will sustain a bullish trend in the stock price over the long term [1]

All three major U.S. stock indexes finished with back-to-back gains on Wednesday, with investors using November's unexpectedly weak private-sector hiring report to solidify expectations for a quarter-point interest-rate cut from the Federal Reserve next week. ...

Core Viewpoint - The Biden administration's fuel-efficiency standards for carmakers require achieving approximately 50 miles per gallon by 2031, while the Trump administration's proposal aims to reduce this requirement to 34.5 miles per gallon [1] Group 1 - The Biden-era rules set a target of 50 miles per gallon for fuel efficiency by 2031 [1] - The Trump administration's proposal would significantly lower the fuel-efficiency requirement to 34.5 miles per gallon [1]

The shortage is a lucrative opportunity — but the window is brief. ...

There's a proxy vote to change the fund, and the calls will keep coming until the matter is settled. ...

ETF investors stuck with tech through a turbulent November. ...

Share prices for both suitors are down over 5% as details emerge of cash bids for the owner of HBO and CNN. ...

Core Viewpoint - Bristol Myers' stock experienced a rally as investors remain optimistic about Cobenfy as a potential Alzheimer's treatment, despite a delay in the outcome of a late-stage trial [1] Group 1 - Investors are maintaining high hopes for Cobenfy, indicating strong market interest and potential for future growth in the Alzheimer's treatment sector [1] - The delay in the late-stage trial outcome has not significantly dampened investor sentiment, suggesting confidence in the drug's prospects [1]

"I am curious as to why Delta didn't ask me, the account holder, whether this was OK.†...

Adjusting sales quotas early in the fiscal year is not surprising, says one analyst who sees weakness in the stock as a buying opportunity. ...